Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
High-dose vitamin D2 softgels
The First People's Hospital of Lianyungang
Chronic Kidney Disease 5D
1 trial -
House dust mite
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Allergic Asthma
1 trial -
Huang-long Zhi-xiao Granule
The First People's Hospital of Lianyungang
Asthma Chronic
1 trial -
Huangjing Yangji Formula Granules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sarcopenia
1 trial -
Huangqi Guizhi Wuwu decoction
The First People's Hospital of Lianyungang
Diabetic Nephropathies
1 trial -
Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin
The First People's Hospital of Lianyungang
Hypertension
1 trial -
Hypofractionated Radiation Therapy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
IORT
The First People's Hospital of Lianyungang
Laryngeal Neoplasms
1 trial -
IPT plus HD-tDCS
The First People's Hospital of Lianyungang
Depressive Disorder
1 trial -
Immunological Factors
COLLEGIUM PHARMACEUTICAL, INC
Neuropathic Pain
1 trial -
Immunosuppressive therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
In-stent Restenosis Lesion
1 trial -
Indometacin suppository
The First People's Hospital of Lianyungang
Pancreatitis, Chronic
1 trial -
Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
Hospital Authority, Hong Kong
CD30+ Peripheral T-cell Lymphoma
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
The First People's Hospital of Lianyungang
CD30+ Peripheral T-cell Lymphoma
1 trial -
Induction therapy-Pro regimen
The First People's Hospital of Lianyungang
Diffuse Large B-Cell Lymphoma
1 trial -
Influence of propofol sedation on memory consolidation and 'working memory'
The First People's Hospital of Lianyungang
Memory Impairment
1 trial -
Infrared thermography
The First People's Hospital of Lianyungang
Chronic Obstructive Pulmonary Disease
1 trial -
Inhaled Placebo
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ventilator-Associated Pneumonia (VAP)
1 trial -
Inhaled corticosteriod/long-acting beta-agonist plus Montelukast
Second Affiliated Hospital, School of Medicine, Zhejiang University
Asthma
1 trial -
Insulin
The First People's Hospital of Lianyungang
Gestational Diabetes
1 trial -
Interleukin-2
The First People's Hospital of Lianyungang
Beta Thalassemia Major
1 trial -
Intestinal Microbiota Transplant (IMT) Capsules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cardiovascular Disease
1 trial -
Intraoperative Radiation Therapy in Malignant Cerebral Tumor
The First People's Hospital of Lianyungang
Glioblastoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources